Shares of Small-cap health care company Supernus Pharmaceuticals moved -0.7 this evening, and are now trading at $23.86 per share. On the other hand, the average analyst target price for the stock is $42.25.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
Supernus Pharmaceuticals Investors Should Consider This:
-
Supernus Pharmaceuticals has moved -31.0% over the last year.
-
The company has a price to earnings growth (PEG) ratio of 8.31. A number between 0 and 1 could mean that the market is undervaluing Supernus Pharmaceuticals's estimated growth potential
-
Its Price to Book (P/B) ratio is 1.42
Understanding Supernus Pharmaceuticals's Operating Margins
| Date Reported | Total Revenue ($ k) | Operating Expenses ($ k) | Operating Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 634,008 | 613,608 | 4 | -55.56 |
| 2022 | 667,238 | 621,114 | 9 | -40.0 |
| 2021 | 579,775 | 493,746 | 15 | -54.55 |
| 2020 | 520,397 | 346,699 | 33 | -13.16 |
| 2019 | 392,755 | 244,184 | 38 | 8.57 |
| 2018 | 408,897 | 264,453 | 35 |
Over the last 6 years, Supernus Pharmaceuticals's operating margins have averaged 22.3%, which is better than the 12.02% Pharmaceutical industry average. We also note that the company's operating margins have a high coefficient of variability at 125.1%. However the firm's margins are declining at a compounded yearly rate of -29.8%.
